GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Beta

Ensol Biosciences (XKRX:140610) Beta : 0.69 (As of Jun. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-24), Ensol Biosciences's Beta is 0.69.


Ensol Biosciences Beta Historical Data

The historical data trend for Ensol Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Beta Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.11 0.44 0.65

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.11 0.44 0.65

Competitive Comparison of Ensol Biosciences's Beta

For the Biotechnology subindustry, Ensol Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Beta falls into.



Ensol Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Ensol Biosciences  (XKRX:140610) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Ensol Biosciences Beta Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences (XKRX:140610) Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines